Understanding how certain myeloma cells depend on Bcl-2 proteins for survival
Regulation of Bcl-2 dependence in multiple myeloma
This study is looking at how certain proteins help some types of multiple myeloma survive, with the goal of finding out which patients might benefit from new treatments that block these proteins, making it easier to personalize care for each person.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-10909073 on NIH RePORTER |
What this research studies
This research investigates the role of Bcl-2 family proteins in multiple myeloma, a type of cancer affecting plasma cells. It aims to identify specific subtypes of myeloma that are dependent on Bcl-2 for survival, which could lead to targeted therapies using Bcl-2 inhibitors like venetoclax. By analyzing the biological mechanisms and signaling pathways involved, the study seeks to develop biomarkers that can predict which patients will benefit from these new treatments. This approach could help tailor therapies to individual patients based on their cancer's unique characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma, particularly those exhibiting a B cell-like phenotype.
Not a fit: Patients with multiple myeloma who do not express Bcl-2 dependence or those with other types of blood cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with multiple myeloma.
How similar studies have performed: Previous research has shown promising results in targeting Bcl-2 in other B cell malignancies, suggesting potential for success in this approach for multiple myeloma.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Gupta, Vikas Anand — Emory University
- Study coordinator: Gupta, Vikas Anand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.